Latest Oncology News

Tilsotolimod Demonstrates Encouraging Activity, Safety in Early-Stage Melanoma

Tilsotolimod Demonstrates Encouraging Activity, Safety in Early-Stage Melanoma

May 23rd 2022

Chris Ryan

The synthetic Toll-like receptor 9 agonist tilsotolimod reduced the sentinel lymph node biopsy positivity rate vs placebo in patients with localized, excised melanoma.

Taylor Provides Insight Into Pirtobrutinib Resistance in CLL

Taylor Provides Insight Into Pirtobrutinib Resistance in CLL

May 23rd 2022

OncLive Staff

Dr Taylor discusses the significance of BTK inhibition in chronic lymphocytic leukemia, describes the key objectives of, and methods used, for the genomic analyses performed by his team, underscores the clinical significance of the data yielded from this research, and outlines where future efforts will focus.

New Research Highlights Racial Disparities in Genomic Profiling

New Research Highlights Racial Disparities in Genomic Profiling

May 23rd 2022

Sylvester Comprehensive Cancer Center

A new study by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine has found that Black women with metastatic breast cancer were less likely to have tumors with treatable genetic variations than white and Asian women.

FDA Grants Priority Review to Mirvetuximab Soravtansine for FRα-High, Platinum-Resistant Ovarian Cancer

FDA Grants Priority Review to Mirvetuximab Soravtansine for FRα-High, Platinum-Resistant Ovarian Cancer

May 23rd 2022

Caroline Seymour

The FDA has accepted and filed a biologics license application for mirvetuximab soravtansine for the treatment of patients with folate receptor alpha–high, platinum-resistant ovarian cancer who have previously received between 1 and 3 systemic therapies.

Tucatinib Plus Trastuzumab Elicits Positive Results in HER2+ Metastatic CRC

Tucatinib Plus Trastuzumab Elicits Positive Results in HER2+ Metastatic CRC

May 23rd 2022

Chris Ryan

The combination of tucatinib and trastuzumab produced promising response rates in patients with previously treated HER2-positive metastatic colorectal cancer.

Latest Oncology Videos

All Oncology News

Daratumumab Plus Combination Therapy May Be New Standard of Care for Newly Diagnosed Multiple Myeloma

September 9th 2021

Darlene Dobkowski, MA

Older patients with newly diagnosed multiple myeloma who are ineligible for chemotherapy or transplant may derive a greater benefit when treated with daratumumab plus lenalidomide and dexamethasone compared with lenalidomide and dexamethasone.

Venetoclax Plus FLAG-IDA Elicits High and Durable Responses in Newly Diagnosed AML

September 9th 2021

Sara Karlovitch

The addition of venetoclax to fludarabine, cytarabine, idarubicin and G-CSF resulted in high complete response rates and enables a high consolidative allogeneic transplantation rate in patients with newly diagnosed acute myeloid leukemia.

Active Engagement of Pulmonology Is a Must in the Multidisciplinary Management of Lung Cancer

September 9th 2021

Caroline Seymour

David J. Feller-Kopman, MD, discusses the imperative role of the pulmonologist in the screening and management of lung cancer.

Dr. Coombs on the Efficacy Results of the BRUIN Study With Pirtobrutinib in CLL

September 9th 2021

Catherine C. Coombs, MD, UNC School of Medicine

Catherine Callaghan Coombs, MD, discusses the efficacy results of the ongoing phase 1/2 BRUIN study with pirtobrutinib in chronic lymphocytic leukemia.

Iberdomide Combination Shows Promise and Tolerability in Multiple Myeloma

September 9th 2021

Jamie Cesanek

Iberdomide combined with dexamethasone and either daratumumab, bortezomib, or carfilzomib showed efficacy and tolerability in patients with relapsed or refractory multiple myeloma.

Phase 2 Data Signal a Potential Role for Neoadjuvant Osimertinib in EGFR-mutant NSCLC

September 9th 2021

Brittany Lovely

Updated data from a phase 2 trial presented at the 2021 World Conference on Lung Cancer showed that neoadjuvant osimertinib induced a pathologic complete response among patients with surgically resectable EGFR-mutant non–small cell lung cancer.

Mobocertinib Elicits Efficacy in Advanced EGFR Exon 20 Insertion+ NSCLC Regardless of Prior Immunotherapy

September 9th 2021

Gina Mauro

Mobocertinib demonstrated clinical activity in previously platinum-treated patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer whether or not they received a prior PD-1/PD-L1 inhibitor.

Dr. Robert on Evaluating Trends in Biomarker Testing in Metastatic NSCLC

September 9th 2021

Nicholas J. Robert, MD

Nicholas Robert, MD, discusses the importance of evaluating trends in biomarker testing in metastatic non–small cell lung cancer.

Dr. Blakely on Utilizing Osimertinib in Resectable EGFR-Mutant NSCLC

September 9th 2021

Collin Blakely MD, PhD

Collin Blakely MD, PhD, discusses the rationale for utilizing osimertinib in resectable EGFR-mutant non–small cell lung cancer.

Final Thoughts on New Developments and Emerging Agents 

September 9th 2021

Harry P. Erba, MD, PhD, Duke Cancer Institute

Panelists conclude by reviewing possible advancements on the horizon in AML such as the potential emergence of Menin inhibitors and bispecific T-cell engagers as well as improved methods for predicting response and preventing relapse.  

NICE Recommends Apalutamide Plus ADT for Prostate Cancer

September 9th 2021

Kristi Rosa

The United Kingdom’s National Institute of Health and Care Excellence has recommended apalutamide for use in combination with androgen deprivation therapy in patients with high-risk hormone-relapsed nonmetastatic prostate cancer and in those with hormone-sensitive metastatic prostate cancer if docetaxel is not suitable or cannot be tolerated.

Treatment Approaches for TP53-Mutated AML

September 9th 2021

Harry P. Erba, MD, PhD, Duke Cancer Institute

Key opinion leaders in hematology oncology share insights into the challenges associated with treating patients with TP53-mutated AML and highlight the recent FDA breakthrough designation of eprenetapopt.

Rapid Readout: Assessment of Tucatinib vs Placebo in the HER2CLIMB Study of Pretreated Patients with HER2+ Metastatic Breast Cancer

September 9th 2021

Giuseppe Curigliano, MD, PhD

Expert oncologist Giuseppe Curigliano, MD, PhD, reflects on the updated results of the HER2CLIMB study evaluating tucatinib against placebo, each in combination with trastuzumab and capecitabine, in patients with pretreated HER2+ metastatic breast cancer.

Future Directions in MDS

September 9th 2021

Yazan Madanat, MD, UT Southwestern Medical Center

Yazan Madanat, MD, and Mikkael A. Sekeres, MD, discuss future directions and novel therapeutic agents for patients with MDS.

ES-SCLC: Trilaciclib for Chemo-Induced Myelosuppression

September 9th 2021

Charu Aggarwal, MD, MPH, University of Pennsylvania Hospital

Jared Weiss, MD, of UNC Lineberger Comprehensive Cancer Center, highlights clinical trial data that led to the approval of trilaciclib in patients receiving a chemotherapy-containing regimen for extensive-stage small cell lung cancer.

See All News